Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. The BUY prediction by melinda for Geron Corp. performed very badly with a performance of -51.11%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 1.459% | 1.459% | -62.984% | -62.439% |
| iShares Core DAX® | 3.002% | 3.742% | 24.169% | 65.664% |
| iShares Nasdaq 100 | 2.966% | 1.308% | 9.141% | 111.170% |
| iShares Nikkei 225® | 5.606% | 4.472% | 21.237% | 55.883% |
| iShares S&P 500 | 2.312% | 1.880% | 6.333% | 67.956% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)